The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Research Report 2025
Synopsis
Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels.
The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Vascular Endothelial Growth Factor (VEGF) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vascular Endothelial Growth Factor (VEGF) Inhibitors.
Report Scope
The Vascular Endothelial Growth Factor (VEGF) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vascular Endothelial Growth Factor (VEGF) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Sanofi.
Segment by Type
VEGF-A Inhibitor
VEGF-B Inhibitor
VEGF-C Inhibitor
VEGF-D Inhibitor
Segment by Application
Oncology
Ophthalmology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels.
The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Vascular Endothelial Growth Factor (VEGF) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vascular Endothelial Growth Factor (VEGF) Inhibitors.
Report Scope
The Vascular Endothelial Growth Factor (VEGF) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vascular Endothelial Growth Factor (VEGF) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Sanofi.
Segment by Type
VEGF-A Inhibitor
VEGF-B Inhibitor
VEGF-C Inhibitor
VEGF-D Inhibitor
Segment by Application
Oncology
Ophthalmology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 VEGF-A Inhibitor
1.2.3 VEGF-B Inhibitor
1.2.4 VEGF-C Inhibitor
1.2.5 VEGF-D Inhibitor
1.3 Market by Application
1.3.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Ophthalmology
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Perspective (2019-2030)
2.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Growth Trends by Region
2.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Dynamics
2.3.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Trends
2.3.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Drivers
2.3.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Challenges
2.3.4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Vascular Endothelial Growth Factor (VEGF) Inhibitors Players by Revenue
3.1.1 Global Top Vascular Endothelial Growth Factor (VEGF) Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue
3.4 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Concentration Ratio
3.4.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue in 2023
3.5 Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Players Head office and Area Served
3.6 Key Players Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Solution and Service
3.7 Date of Enter into Vascular Endothelial Growth Factor (VEGF) Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Breakdown Data by Type
4.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Forecasted Market Size by Type (2025-2030)
5 Vascular Endothelial Growth Factor (VEGF) Inhibitors Breakdown Data by Application
5.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2019-2030)
6.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2019-2024)
6.4 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2019-2030)
7.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2019-2024)
7.4 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2019-2030)
9.2 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Detail
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Introduction
11.1.4 Bayer AG Revenue in Vascular Endothelial Growth Factor (VEGF) Inhibitors Business (2019-2024)
11.1.5 Bayer AG Recent Development
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 F. Hoffmann-La Roche Ltd. Company Detail
11.2.2 F. Hoffmann-La Roche Ltd. Business Overview
11.2.3 F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Introduction
11.2.4 F. Hoffmann-La Roche Ltd. Revenue in Vascular Endothelial Growth Factor (VEGF) Inhibitors Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Ltd. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Introduction
11.3.4 Novartis AG Revenue in Vascular Endothelial Growth Factor (VEGF) Inhibitors Business (2019-2024)
11.3.5 Novartis AG Recent Development
11.4 Regeneron Pharmaceuticals Inc.
11.4.1 Regeneron Pharmaceuticals Inc. Company Detail
11.4.2 Regeneron Pharmaceuticals Inc. Business Overview
11.4.3 Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Introduction
11.4.4 Regeneron Pharmaceuticals Inc. Revenue in Vascular Endothelial Growth Factor (VEGF) Inhibitors Business (2019-2024)
11.4.5 Regeneron Pharmaceuticals Inc. Recent Development
11.5 Sanofi.
11.5.1 Sanofi. Company Detail
11.5.2 Sanofi. Business Overview
11.5.3 Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Introduction
11.5.4 Sanofi. Revenue in Vascular Endothelial Growth Factor (VEGF) Inhibitors Business (2019-2024)
11.5.5 Sanofi. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
